View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 20, 2022updated 27 Jul 2022 9:39am

Avista and Roche to develop gene therapy vectors for eyes

Avista is entitled to receive $7.5m in upfront payment from Roche.

Avista Therapeutics, a University of Pittsburgh Medical Center (UPMC) spinout, has entered a collaboration with Roche for developing new AAV gene therapy vectors for eyes.

The alliance plans to leverage the single-cell adeno-associated virus (AAV) engineering (scAAVengr) platform technology of Avista to develop intravitreal AAV capsids for a Roche-defined profile.

According to the deal, Roche holds the right to analyse and licence new capsids from Avista.

Roche will use these new capsids to carry out preclinical, clinical and marketing activities for gene therapy programmes.

These capsids will be different from the internal pipeline of Avista.

Avista is entitled to receive $7.5m in upfront payment from Roche.

Roche will also make further payments to Avista during the collaboration’s research phase and clinical, sales-based milestone and royalty payments for resulting products.

These payments of the deal would potentially total over $1bn.

Avista’s computationally steered, in vivo scAAVengr platform uses a high-throughput method with the integrated quantitative validation of new cell-specific AAVs.

This aids in quickly advancing transformative gene therapies to clinical trials for ophthalmic ailments.

In addition, the company will create a pipeline based on AAV variants’ toolkit that can act on gene delivery to separate retinal cell types.

Avista Therapeutics CEO Robert Lin said: “We are excited to enter into this collaboration with Roche, a global leader in health care.

“This collaboration will complement our in-house pipeline and will accelerate the delivery of transformative therapies to patients.”

The company raised $10m in seed funding and received UPMC Enterprises’ foundational support.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology